184 related articles for article (PubMed ID: 34682281)
1. Genetic Analyses of Amphotericin B Susceptibility in
Fan Y; Korfanty GA; Xu J
J Fungi (Basel); 2021 Oct; 7(10):. PubMed ID: 34682281
[No Abstract] [Full Text] [Related]
2. Comparative Genome Sequence Analyses of Geographic Samples of
Fan Y; Wang Y; Xu J
Microorganisms; 2020 Oct; 8(11):. PubMed ID: 33126611
[TBL] [Abstract][Full Text] [Related]
3. Widespread amphotericin B-resistant strains of
Ashu EE; Korfanty GA; Samarasinghe H; Pum N; You M; Yamamura D; Xu J
Infect Drug Resist; 2018; 11():1549-1555. PubMed ID: 30288065
[TBL] [Abstract][Full Text] [Related]
4. Identifying genetic variants associated with amphotericin B (AMB) resistance in
Chen MM; Shi GH; Dai Y; Fang WX; Wu Q
Front Genet; 2023; 14():1133593. PubMed ID: 37229189
[No Abstract] [Full Text] [Related]
5. In vitro susceptibilities of Aspergillus species to voriconazole, itraconazole, and amphotericin B.
Abraham OC; Manavathu EK; Cutright JL; Chandrasekar PH
Diagn Microbiol Infect Dis; 1999 Jan; 33(1):7-11. PubMed ID: 9990469
[TBL] [Abstract][Full Text] [Related]
6. In vitro activities of amphotericin B and AmBisome against Aspergillus isolates recovered from Italian patients treated for haematological malignancies.
Colozza C; Posteraro B; Santilli S; De Carolis E; Sanguinetti M; Girmenia C
Int J Antimicrob Agents; 2012 May; 39(5):440-3. PubMed ID: 22429723
[TBL] [Abstract][Full Text] [Related]
7. Increased frequency of non-fumigatus Aspergillus species in amphotericin B- or triazole-pre-exposed cancer patients with positive cultures for aspergilli.
Lionakis MS; Lewis RE; Torres HA; Albert ND; Raad II; Kontoyiannis DP
Diagn Microbiol Infect Dis; 2005 May; 52(1):15-20. PubMed ID: 15878437
[TBL] [Abstract][Full Text] [Related]
8. In vitro interaction between alginate lyase and amphotericin B against Aspergillus fumigatus biofilm determined by different methods.
Bugli F; Posteraro B; Papi M; Torelli R; Maiorana A; Paroni Sterbini F; Posteraro P; Sanguinetti M; De Spirito M
Antimicrob Agents Chemother; 2013 Mar; 57(3):1275-82. PubMed ID: 23263007
[TBL] [Abstract][Full Text] [Related]
9. Prior in vitro exposure to voriconazole confers resistance to amphotericin B in Aspergillus fumigatus biofilms.
Rajendran R; Mowat E; Jones B; Williams C; Ramage G
Int J Antimicrob Agents; 2015 Sep; 46(3):342-5. PubMed ID: 25979638
[TBL] [Abstract][Full Text] [Related]
10. Intrinsic in vitro susceptibility of primary clinical isolates of Aspergillus fumigatus, Aspergillus terreus, Aspergillus nidulans, Candida albicans and Candida lusitaniae against amphotericin B.
Singh J; Rimek D; Kappe R
Mycoses; 2006 Mar; 49(2):96-103. PubMed ID: 16466441
[TBL] [Abstract][Full Text] [Related]
11. [A pharmacodynamics study of an intravitreal amphotericin B drug delivery system for the treatment of experimental Aspergillus fumigatus endophthalmitis].
Yang X; Dong XG; Liu AM; Sun SY; Xie LX; Wang SG
Zhonghua Yan Ke Za Zhi; 2007 Jun; 43(6):546-53. PubMed ID: 17897534
[TBL] [Abstract][Full Text] [Related]
12. Synergistic interaction of the triple combination of amphotericin B, ciprofloxacin, and polymorphonuclear neutrophils against Aspergillus fumigatus.
Stergiopoulou T; Meletiadis J; Sein T; Papaioannidou P; Walsh TJ; Roilides E
Antimicrob Agents Chemother; 2011 Dec; 55(12):5923-9. PubMed ID: 21911564
[TBL] [Abstract][Full Text] [Related]
13. Antifungal resistance in Aspergillus terreus: A current scenario.
Vahedi Shahandashti R; Lass-Flörl C
Fungal Genet Biol; 2019 Oct; 131():103247. PubMed ID: 31247322
[TBL] [Abstract][Full Text] [Related]
14.
Seyedmousavi S; Mouton JW; Melchers WJG; Verweij PE
Antimicrob Agents Chemother; 2017 Jun; 61(6):. PubMed ID: 28416540
[TBL] [Abstract][Full Text] [Related]
15. Effects of amphotericin B on Aspergillus flavus clinical isolates with variable susceptibilities to the polyene in an experimental model of systemic aspergillosis.
Barchiesi F; Spreghini E; Sanguinetti M; Giannini D; Manso E; Castelli P; Girmenia C
J Antimicrob Chemother; 2013 Nov; 68(11):2587-91. PubMed ID: 23794598
[TBL] [Abstract][Full Text] [Related]
16. Comparative in vitro antifungal activity of amphotericin B lipid complex, amphotericin B and fluconazole.
Carrillo-Muñoz AJ; Quindós G; Tur C; Ruesga M; Alonso R; del Valle O; Rodriguez V; Arévalo MP; Salgado J; Martin-Mazuelos E; Bornay-Llinares FJ; del Palacio A; Cuétara M; Gasser I; Hernández-Molina JM; Pemán J
Chemotherapy; 2000; 46(4):235-44. PubMed ID: 10859429
[TBL] [Abstract][Full Text] [Related]
17. Management of cerebral azole-resistant Aspergillus fumigatus infection: A role for intraventricular liposomal-amphotericin B.
Schauwvlieghe AFAD; Bredius RGM; Verdijk RM; Smiers FJW; van der Beek MT; Goemans BF; Zwaan CM; Brüggemann RJ; Rijnders BJA
J Glob Antimicrob Resist; 2020 Sep; 22():354-357. PubMed ID: 32251868
[TBL] [Abstract][Full Text] [Related]
18. In vitro and in vivo activities of NS-718, a new lipid nanosphere incorporating amphotericin B, against Aspergillus fumigatus.
Otsubo T; Maesaki S; Hossain MA; Yamamoto Y; Tomono K; Tashiro T; Seki J; Tomii Y; Sonoke S; Kohno S
Antimicrob Agents Chemother; 1999 Mar; 43(3):471-5. PubMed ID: 10049253
[TBL] [Abstract][Full Text] [Related]
19. In vitro and in vivo role of heat shock protein 90 in Amphotericin B resistance of Aspergillus terreus.
Blum G; Kainzner B; Grif K; Dietrich H; Zeiger B; Sonnweber T; Lass-Flörl C
Clin Microbiol Infect; 2013 Jan; 19(1):50-55. PubMed ID: 22515428
[TBL] [Abstract][Full Text] [Related]
20. International expert opinion on the management of infection caused by azole-resistant Aspergillus fumigatus.
Verweij PE; Ananda-Rajah M; Andes D; Arendrup MC; Brüggemann RJ; Chowdhary A; Cornely OA; Denning DW; Groll AH; Izumikawa K; Kullberg BJ; Lagrou K; Maertens J; Meis JF; Newton P; Page I; Seyedmousavi S; Sheppard DC; Viscoli C; Warris A; Donnelly JP
Drug Resist Updat; 2015; 21-22():30-40. PubMed ID: 26282594
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
